Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic A Puri, K Loomis, B Smith, JH Lee, A Yavlovich, E Heldman, R Blumenthal Critical Reviews™ in Therapeutic Drug Carrier Systems 26 (6), 2009 | 1258 | 2009 |
Nanoparticles with targeting, triggered release, and imaging functionality for cancer applications K Loomis, K McNeeley, RV Bellamkonda Soft Matter 7 (3), 839-856, 2011 | 152 | 2011 |
Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection E Boeggeman, B Ramakrishnan, M Pasek, M Manzoni, A Puri, KH Loomis, ... Bioconjugate chemistry 20 (6), 1228-1236, 2009 | 134 | 2009 |
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2+ affisomes) B Smith, I Lyakhov, K Loomis, D Needle, U Baxa, A Yavlovich, J Capala, ... Journal of controlled release 153 (2), 187-194, 2011 | 113 | 2011 |
Nanocarrier-mediated inhibition of macrophage migration inhibitory factor attenuates secondary injury after spinal cord injury T Saxena, KH Loomis, SB Pai, L Karumbaiah, E Gaupp, K Patil, R Patkar, ... ACS nano 9 (2), 1492-1505, 2015 | 102 | 2015 |
Characterizing exogenous mRNA delivery, trafficking, cytoplasmic release and RNA–protein correlations at the level of single cells JL Kirschman, S Bhosle, D Vanover, EL Blanchard, KH Loomis, C Zurla, ... Nucleic Acids Research, 2017 | 78 | 2017 |
Isolation and characterization of diverse microbial representatives from the human skin microbiome CM Timm, K Loomis, W Stone, T Mehoke, B Brensinger, M Pellicore, ... Microbiome 8, 1-12, 2020 | 68 | 2020 |
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv K Loomis, B Smith, Y Feng, H Garg, A Yavlovich, R Campbell-Massa, ... Experimental and molecular pathology 88 (2), 238-249, 2010 | 56 | 2010 |
A mixed community of skin microbiome representatives influences cutaneous processes more than individual members KH Loomis, SK Wu, A Ernlund, K Zudock, A Reno, K Blount, DK Karig Microbiome 9, 1-17, 2021 | 55 | 2021 |
In Vitro Transcribed mRNA Vaccines with Programmable Stimulation of Innate Immunity KH Loomis, KE Lindsay, C Zurla, SM Bhosle, DA Vanover, EL Blanchard, ... Bioconjugate Chemistry 29 (9), 3072-3083, 2018 | 32 | 2018 |
Unifying in vitro and in vivo IVT mRNA expression discrepancies in skeletal muscle via mechanotransduction SM Bhosle, KH Loomis, JL Kirschman, EL Blanchard, DA Vanover, ... Biomaterials 159, 189-203, 2018 | 29 | 2018 |
Strategies for modulating innate immune activation and protein production of in vitro transcribed mRNAs KH Loomis, JL Kirschman, S Bhosle, RV Bellamkonda, PJ Santangelo Journal of materials chemistry B 4 (9), 1619-1632, 2016 | 27 | 2016 |
Multiple Site-Specific in Vitro Labeling of Single-Chain Antibody B Ramakrishnan, E Boeggeman, M Manzoni, Z Zhu, K Loomis, A Puri, ... Bioconjugate chemistry 20 (7), 1383-1389, 2009 | 24 | 2009 |
Proximity ligation assays for in situ detection of innate immune activation: focus on in vitro-transcribed mRNA EL Blanchard, KH Loomis, SM Bhosle, D Vanover, P Baumhof, B Pitard, ... Molecular Therapy Nucleic Acids 14, 52-66, 2019 | 20 | 2019 |
STRATEGIES FOR CONTROLLING THE INNATE IMMUNE RESPONSES TO IN VITRO TRANSCRIBED MESSENGER RNAS KH Loomis Georgia Institute of Technology, 2016 | | 2016 |
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2⁺ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2⁺ affisomes) B Smith, I Lyakhov, K Loomis, D Needle, U Baxa, A Yavlovich, J Capala, ... | | 2011 |